title: Steady-state pharmacokinetics of oral sustained-release morphine sulphate in dogs.
abstract: The pharmacokinetics of steady-state oral sustained-release morphine sulphate (OSRMS) were studied in dogs. Beagles (n = 6) were randomly assigned to one of two treatment groups. Treatments included 15 mg OSRMS every 8 h for 4 days, or 15 mg OSRMS every 12 h for 4 days. Serum samples, drawn at intervals for the final 24 h of drug administration were analysed for morphine concentration using radioimmunoassay. Pharmacokinetic analysis revealed that there were no significant differences between trough serum concentrations for the concentration-time curves within either treatment group, indicating that steady-state pharmacokinetics had been achieved. There were no significant differences in time to maximum serum concentration among the three sections of the concentration-time curve for the 8-h group or between the two sections of the curve for the 12-h group. Area under the concentration-time curve and maximum serum concentrations were significantly greater for the section of the curve following dosing at 7:30 h than following dosing at 19:30 h in the 12-h treatment group. This chronopharmacokinetic variability was not present in the 8-h treatment group. OSRMS provides sustained periods of elevated serum concentrations following administration every 8 or 12 h at a clinically applicable dosage. The clinical implications of the chronopharmacokinetic variability seen with 12-hourly administration are not known. This formulation has potential for the treatment of chronic pain in dogs, but further studies of efficacy and safety following long-term administration are required.
authors.affiliation: Department of Anatomy and Physiology, Atlantic Veterinary College, University of P.E.I., Charlottetown, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Dohoo
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D003692:Delayed-Action Preparations; D004285:Dogs / Q000097:blood*; D005260:Female; D008954:Models, Biological; D009020:Morphine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011863:Radioimmunoassay; D011897:Random Allocation
chemical_list: D003692:Delayed-Action Preparations; D009020:Morphine